Danaher Company Profile (NYSE:DHR)

Danaher trades on the New York Stock Exchange (NYSE) under the ticker symbol "DHR."

Danaher announced a quarterly dividend on Tuesday, September 12th. Investors of record on Friday, September 29th will be paid a dividend of $0.14 per share on Friday, October 27th. This represents a $0.56 dividend on an annualized basis and a yield of 0.66%. The ex-dividend date of this dividend is Thursday, September 28th. View Danaher's Dividend History.

Danaher Co. (NYSE:DHR) issued its quarterly earnings data on Thursday, July, 20th. The company reported $0.99 EPS for the quarter, topping the consensus estimate of $0.97 by $0.02. The business had revenue of $4.51 billion for the quarter, compared to the consensus estimate of $4.50 billion. Danaher had a return on equity of 9.24% and a net margin of 12.36%. Danaher's quarterly revenue was up 6.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.90 earnings per share. View Danaher's Earnings History.

Danaher is scheduled to release their next quarterly earnings announcement on Thursday, October, 19th 2017. View Earnings Estimates for Danaher.

Danaher issued an update on its FY17 earnings guidance on Thursday, July, 20th. The company provided EPS guidance of $3.90-3.97 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.93. Danaher also updated its Q3 guidance to $0.92-0.96 EPS.

15 analysts have issued 1-year price objectives for Danaher's shares. Their predictions range from $83.00 to $97.00. On average, they expect Danaher's stock price to reach $92.13 in the next twelve months. View Analyst Ratings for Danaher.

Here are some recent quotes from research analysts about Danaher stock:

• 1. According to Zacks Investment Research, "Year-to-date, Danaher’s shares have outperformed the industry’s average return. The company has an excellent earnings history over the trailing four quarters, beating estimates all through. We are optimistic about the company’s core revenue and earnings growth, on the back of improving order trends and its operating culture, DBS. Going forward, the company expects the biopharma business to be a major growth driver. Its recent acquisitions - Pall and Cepheid – are proving to be strong profit churners, and will boost top-line growth as they become a part of the company’s core revenues. However, on the flip side, slowdown in the company’s academic business in Europe and prolonged sluggishness in the Dental business has restricted growth. Weakness in industrial markets and stiff competition may also hurt the company's financials." (10/5/2017)
• 2. Jefferies Group LLC analysts commented, "Following a solid 4Q beat, our '17 forecasts feel incrementally conservative, given strong core margin progress & encouraging signs of better demand in certain industrial pockets. With core growth poised to accelerate in '17 (and '18) & ample margin expansion levers on-hand, we maintain our Buy rating." (2/1/2017)
• 3. Evercore ISI analysts commented, "DHR delivered a quarter generally consistent with expectations as core growth remains on an upward trajectory, OMx is solid given the flurry of deals over the past 24 months and FCF conversion is elevated (another form of synergy capture from M&A). We believe investors have aptly rewarded the result, with today's move in shares indicative of a flee to safety and predictability in what is otherwise a challenging Healthcare tape. Given potential cyclical upside should global GDP growth accelerate and a reasonably strong B/S to continue capital allocation in 2017 and beyond we believe DHR's elevated valuation is justified and thus it remains our 'Top Pick' within a Tools complex we favor overall. Furthermore, we believe that while the Dental market has proven frustrating, the asset is of high quality and long-term investors will be pleased to either see the business generate improved / superior returns or be monetized (via sale / spin) for more than is implied in current valuation." (1/31/2017)

Some companies that are related to Danaher include Thermo Fisher Scientific (TMO), Boston Scientific (BSX), Intuitive Surgical (ISRG), Koninklijke Philips N.V. (PHG), Illumina (ILMN), Cerner Corporation (CERN), Edwards Lifesciences Corporation (EW), Agilent Technologies (A), Waters Corporation (WAT), ResMed (RMD), Hologic (HOLX), Varian Medical Systems (VAR), PerkinElmer (PKI), ABIOMED (ABMD), Bruker Corporation (BRKR), Alere (ALR), Quidel Corporation (QDEL) and Mazor Robotics (MZOR).

Danaher's management team includes the folowing people:

• Steven M. Rales, Chairman of the Board
• Daniel L. Comas, Chief Financial Officer, Executive Vice President
• Rainer M. Blair, Executive Vice President
• William K. Daniel II, Executive Vice President
• Robert S. Lutz, Senior Vice President, Chief Accounting Officer
• Brian W. Ellis, Senior Vice President, General Counsel
• Angela S. Lalor, Senior Vice President - Human Resources
• William H. King, Senior Vice President - Strategic Development
• Daniel A. Raskas, Senior Vice President - Corporate Development
• Thomas Patrick Joyce Jr., President, Chief Executive Officer, Director

Danaher's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Park National Corp OH (0.02%), Osborn Williams & Donohoe LLC (0.01%), Neville Rodie & Shaw Inc. (0.01%), Bath Savings Trust Co (0.01%), Curbstone Financial Management Corp (0.00%) and Fulton Bank N.A. (0.00%). Company insiders that own Danaher stock include Angela S Lalor, Brian W Ellis, Daniel L Comas, Daniel Raskas, Donald J Ehrlich, James A Lico, Linda P Hefner, Robert S Lutz, Thomas Patrick Joyce Jr, Thomas Patrick Joyce, Jr, Walter G Lohr, William K Daniel and William King. View Institutional Ownership Trends for Danaher.

Danaher's stock was sold by a variety of institutional investors in the last quarter, including Osborn Williams & Donohoe LLC. Company insiders that have sold Danaher stock in the last year include Angela S Lalor, Brian W Ellis, Donald J Ehrlich, Linda P Hefner, Robert S Lutz, Thomas Patrick Joyce Jr, Walter G Lohr, William K Daniel and William King. View Insider Buying and Selling for Danaher.

Danaher's stock was purchased by a variety of institutional investors in the last quarter, including Park National Corp OH, Bath Savings Trust Co, Fulton Bank N.A., Neville Rodie & Shaw Inc. and Curbstone Financial Management Corp. View Insider Buying and Selling for Danaher.

Shares of Danaher can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Danaher stock can currently be purchased for approximately $85.26.